{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:36:44Z","timestamp":1793039804327,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer, BMS, Sankyo"},{"name":"EDRA S.p.A.; European Union\u2019s Horizon 2020 research and innovation programme","award":["675527"],"award-info":[{"award-number":["675527"]}]},{"name":"MIUR Progetto Eccellenza"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.phrs.2018.07.016","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T11:46:22Z","timestamp":1532173582000},"page":"60-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)"],"prefix":"10.1016","volume":"135","author":[{"given":"Paolo","family":"Gelosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castiglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tenconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-557X","authenticated-orcid":false,"given":"Ludovico","family":"Baldessin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Racagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-7824","authenticated-orcid":false,"given":"Stefano","family":"Bellosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2016","key":"10.1016\/j.phrs.2018.07.016_bib0005","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0010","first-page":"1031","article-title":"Outpatient management of anticoagulation therapy","volume":"75","author":"du Breuil","year":"2007","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.phrs.2018.07.016_bib0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14740338.5.3.433","article-title":"Warfarin and its interactions with foods, herbs and other dietary supplements","volume":"5","author":"Nutescu","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2018.07.016_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-9560-12-20","article-title":"Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study","volume":"12","author":"Teklay","year":"2014","journal-title":"Thromb. J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.phrs.2018.07.016_bib0035","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","article-title":"Prosthetic heart valve thrombosis","volume":"68","author":"Dangas","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0060","first-page":"343","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc. Heal. Risk Manag."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2018.07.016_bib0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.phrs.2016.08.006","article-title":"Pharmacological treatments of cardiovascular diseases: evidence from real-life studies","volume":"118","author":"Salvo","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0075","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.07.016_bib0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1076029613486539","article-title":"The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis","volume":"19","author":"Mitchell","year":"2013","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2013.07.009","article-title":"Disadvantages of VKA and requirements for novel anticoagulants","volume":"26","author":"Shameem","year":"2013","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0100","doi-asserted-by":"crossref","first-page":"g4517","DOI":"10.1136\/bmj.g4517","article-title":"Dabigatran, bleeding, and the regulators","volume":"349","author":"Moore","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2018.07.016_bib0105","first-page":"1","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","author":"Steffel","year":"2018","journal-title":"EP Eur."},{"key":"10.1016\/j.phrs.2018.07.016_bib0110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.phrs.2017.01.004","article-title":"Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): a systematic review and meta-analysis on gender differences","volume":"117","author":"Proietti","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0304-4165(86)90238-2","article-title":"The in vivo effects of acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and vitamin K-dependent carboxylase in various tissues of the rat","volume":"884","author":"de Boer-van den Berg","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2018.07.016_bib0125","unstructured":"FDA, Coumadin, Summary of Products Characteristics, (n.d.) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf."},{"key":"10.1016\/j.phrs.2018.07.016_bib0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40256-013-0061-0","article-title":"New oral anticoagulants in practice: pharmacological and practical considerations","volume":"14","author":"Wang","year":"2014","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2018.07.016_bib0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cger.2005.09.001","article-title":"Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly","volume":"22","author":"Jacobs","year":"2006","journal-title":"Clin. Geriatr. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","article-title":"New oral anticoagulants: comparative pharmacology with vitamin K antagonists","volume":"52","author":"Scaglione","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/j.1552-4604.2000.tb05992.x","article-title":"Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects","volume":"40","author":"Karim","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00542190","article-title":"Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man","volume":"32","author":"Toon","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0155","first-page":"7","article-title":"The predictive nature of high-throughput toxicity screening using a human hepatocyte cell line","author":"Sussman","year":"2002","journal-title":"Cell Notes"},{"key":"10.1016\/j.phrs.2018.07.016_bib0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/bdd.2055","article-title":"Role of ABC transporters in trans-epithelial transport of vitamin K antagonists","volume":"38","author":"Espana","year":"2017","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00008571-199512000-00008","article-title":"Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy","volume":"5","author":"Furuya","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2018.07.016_bib0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008571-199810000-00001","article-title":"Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes","volume":"8","author":"Takahashi","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2018.07.016_bib0180","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.12220","article-title":"Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon","volume":"77","author":"Verhoef","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0185","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1538-7836.2012.04633.x","article-title":"Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users","volume":"10","author":"Verhoef","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.tpj.6500220","article-title":"Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors","volume":"4","author":"Wadelius","year":"2004","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0195","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0200","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"ADVANCE-2 investigators, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.07.016_bib0205","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0210","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0215","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0220","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0225","unstructured":"FDA, Eliquis label information, (n.d.) www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0230","unstructured":"EMA, Eliquis, Summary of Product Characteristics, (n.d.) http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf. (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0240","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0245","first-page":"19","article-title":"Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects (abstract 1703161)","volume":"2","author":"Frost","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.phrs.2018.07.016_bib0250","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.clinthera.2016.05.004","article-title":"Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults","volume":"38","author":"Song","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0255","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0260","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-Drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0265","first-page":"1132","article-title":"Apixaban,adirectfactorXainhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation","volume":"48","author":"Frost","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0270","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0275","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-014-0228-0","article-title":"Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban","volume":"54","author":"Frost","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0280","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tips.2005.11.009","article-title":"Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs","volume":"27","author":"Breedveld","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2018.07.016_bib0285","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.blre.2017.02.002","article-title":"Advances in oral anticoagulation therapy \u2013 what\u2019s in the pipeline?","volume":"31","author":"Rao","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.phrs.2018.07.016_bib0290","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1124\/dmd.108.025981","article-title":"Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0295","unstructured":"CLINICAL TRIAL.GOV, (n.d.) https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=apixaban&cntry=&state=&city=&dist= (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0300","first-page":"19","article-title":"The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects","volume":"9","author":"Frost","year":"2017","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"10.1016\/j.phrs.2018.07.016_bib0305","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/1060028014523115","article-title":"Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications","volume":"48","author":"Egan","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2018.07.016_bib0310","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0315","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in Nonvalvular Atrial Fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2018.07.016_bib0320","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eplepsyres.2016.06.003","article-title":"Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs","volume":"126","author":"St\u00f6llberger","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0325","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40256-015-0157-9","article-title":"Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa","volume":"16","author":"Vakkalagadda","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2018.07.016_bib0330","first-page":"59","article-title":"Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"5","author":"Upreti","year":"2013","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"10.1016\/j.phrs.2018.07.016_bib0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","author":"Wang","year":"2014","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2018.07.016_bib0340","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ahj.2016.12.004","article-title":"The safety and efficacy of full- versus reduced-dose betrixaban in the acute medically Ill VTE (Venous Thromboembolism) prevention with Extended-Duration Betrixaban (APEX) trial","volume":"185","author":"Gibson","year":"2017","journal-title":"Am Hear. J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0350","author":"U.S.F. and D. Administration","year":"2017","journal-title":"FDA Approved Betrixaban (BEVYXXA, Portola) for the Prophylaxis of Venous Thromboembolism (VTE) in Adult Patients"},{"key":"10.1016\/j.phrs.2018.07.016_bib0355","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2018.07.016_bib0360","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0365","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656566.2013.753057","article-title":"Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study","volume":"14","author":"Morganroth","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2018.07.016_bib0370","unstructured":"FDA, Bevyxxa label information, (n.d.) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208383s000lbl.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0375","first-page":"85","article-title":"Betrixaban (Bevyxxa): a direct-acting oral anticoagulant factor Xa inhibitor","volume":"43","author":"Skelley","year":"2018","journal-title":"PT"},{"key":"10.1016\/j.phrs.2018.07.016_bib0380","first-page":"2266","article-title":"Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes","volume":"120","author":"Hutchaleelaha","year":"2012","journal-title":"Blood ASH Ann Meet Abstr."},{"key":"10.1016\/j.phrs.2018.07.016_bib0385","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2013.11.006","article-title":"The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study","volume":"167","author":"Cohen","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0390","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/17474086.2016.1256194","article-title":"Betrixaban - the next direct factor Xa inhibitor?","volume":"9","author":"Thoenes","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0395","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators, Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0400","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0405","unstructured":"FDA, Pradaxa label information, (n.d.). FDA, Pradaxa label information www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022512s035lbl.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0410","unstructured":"EMA, Pradaxa, Summary of Products Characteristics., (n.d.) www.ema.europa.eu\/ema\/index.jsp?curl=search.jsp&q=dabigatran+product+information&btnG=Search&mid= (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0415","unstructured":"Pradax, Product monograph. Canada: Boehringer Ingelheim, 2012, (n.d.) https:\/\/www.boehringer-ingelheim.ca\/sites\/ca\/files\/documents\/pradaxapmen.pdf (Accessed 1 May 2017)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0420","unstructured":"Japan for stroke prevention in atrial fibrillation. 2011, (n.d.) www.businesswire.com\/news\/home\/20110121005341\/en\/PRAZAXA%C2%AE-dabigatran-etexilate-Approved-Japan-Stroke-Prevention (Accessed 1 May 2017)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0425","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin","volume":"74","author":"H\u00e4rtter","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0430","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Par\u00e9","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.016_bib0435","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0440","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0091270006297228","article-title":"Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery","volume":"47","author":"Troc\u00f3niz","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0445","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0091270010393342","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin","volume":"52","author":"Stangier","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0450","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0455","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2018.07.016_bib0465","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0470","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF03256595","article-title":"Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics","volume":"9","author":"Stangier","year":"2009","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2018.07.016_bib0475","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa(\u00ae)) after co-medication with verapamil in healthy subjects","volume":"75","author":"H\u00e4rtter","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0480","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0485","first-page":"618","article-title":"Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects (abstract P3566)","volume":"32","author":"Brunet","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0490","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1503\/cmaj.160303","article-title":"Canadian Drug Safety and Effectiveness Research Network, Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation","volume":"189","author":"Antoniou","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.phrs.2018.07.016_bib0495","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.104.002477","article-title":"Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1","volume":"33","author":"Chen","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0500","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","article-title":"Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-Mediated metabolism and MDR1-Mediated transport","volume":"23","author":"Sakaeda","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0505","unstructured":"FDA, Dabigatran etexilate, Advisory Committee Briefing Document, (n.d.) http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterial\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM226009.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0510","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ki.2014.66","article-title":"Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat","volume":"86","author":"Lepist","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2018.07.016_bib0515","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1161\/CIRCULATIONAHA.116.025257","article-title":"Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-Negative healthy volunteers","volume":"134","author":"Gordon","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.016_bib0520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs R."},{"key":"10.1016\/j.phrs.2018.07.016_bib0525","first-page":"P1612","article-title":"Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects","volume":"3","author":"Stangier","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0530","unstructured":"Daiichi Sankyo, (n.d.) www.daiichisankyo.com\/media_investors\/media_relations\/press_releases\/detail\/006314.html (Accessed 1 June 2017)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0535","unstructured":"FDA, Savaysa label information, (n.d.) https:\/\/www.accessdata.fda.gov\/drugsatfda{_}docs\/label\/2015\/206316lbl.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0540","unstructured":"EMA, Lixiana, Summary of Products Characteristics., (n.d.). www.google.com\/search?q=ema+edoxaban+approval&ie=utf-8&oe=utf-8&client=firefox-b (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0545","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-014-0229-7","article-title":"Population pharmacokinetics and dose-exposure proportionality of edoxaban in healthy volunteers","volume":"34","author":"Yin","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.phrs.2018.07.016_bib0550","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0555","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0560","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/dmd.113.054866","article-title":"Edoxaban transport via P-glycoprotein is a key factor for the drug\u2019s disposition","volume":"42","author":"Mikkaichi","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0565","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.07.016_bib0570","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.TP.0000130981.55654.78","article-title":"MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients","volume":"78","author":"Bonhomme-Faivre","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.phrs.2018.07.016_bib0575","first-page":"1091","article-title":"Effect of renal function on edoxaban pharmacokinetics and on population PK\/PK-PD Model","volume":"49","author":"Ridout","year":"2009","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2018.07.016_bib0580","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpdd.329","article-title":"Population pharmacokinetics of edoxaban in japanese atrial fibrillation patients with severe renal impairment","volume":"6","author":"Shimizu","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.phrs.2018.07.016_bib0585","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0590","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","article-title":"Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor","volume":"13","author":"Mendell","year":"2013","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.phrs.2018.07.016_bib0595","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/FJC.0b013e31826265b6.","article-title":"Pharmacokinetics of the direct factor xa inhibitor edoxaban and digoxin administered alone and in combination","volume":"60","author":"Mendell","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0600","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0605","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40261-015-0298-2","article-title":"The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults","volume":"35","author":"Mendell","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.phrs.2018.07.016_bib0610","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0615","first-page":"13","article-title":"Effect of esomeprazole on edoxaban pharmacokinetics and pharmacodynamics when administered orally as tablet and as solution","author":"Mendell","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.phrs.2018.07.016_bib0620","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb. J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0625","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2018.07.016_bib0630","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arter. Thromb Vasc Biol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0635","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arter. Thromb Vasc Biol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0640","author":"Xarelto","year":"2015","journal-title":"Xarelto\u00ae (Rivaroxaban). Summary of Product Characteristics"},{"key":"10.1016\/j.phrs.2018.07.016_bib0645","doi-asserted-by":"crossref","DOI":"10.1177\/2048872617745003","article-title":"Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: insights from the ATLAS ACS 2-TIMI 51 trial","author":"Korjian","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care."},{"key":"10.1016\/j.phrs.2018.07.016_bib0650","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2018.07.016_bib0655","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.phrs.2018.07.016_bib0660","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-013-1029-2","article-title":"A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban","volume":"38","author":"Kreutz","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.phrs.2018.07.016_bib0665","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0670","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0675","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0680","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0685","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0690","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0695","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0700","unstructured":"FDA, Xarelto label information, (n.d.) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022406s015lbl.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0705","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CPP45335","article-title":"Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects","volume":"45","author":"Mueck","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0710","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0715","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0720","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.108.025551","article-title":"In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans","volume":"37","author":"Lang","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.016_bib0725","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0730","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1177\/030006051204000508","article-title":"Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects","volume":"40","author":"Kubitza","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0735","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ahj.2016.01.004","article-title":"A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study","volume":"174","author":"Povsic","year":"2016","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0740","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0745","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/FJC.0b013e31822f6c2b","article-title":"Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban","volume":"58","author":"Moore","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0750","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.phrs.2018.04.019","article-title":"Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation","volume":"132","author":"Shahid","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0755","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"Dec. 45","key":"10.1016\/j.phrs.2018.07.016_bib0760","first-page":"3155","volume":"35","author":"LiP","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0765","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.phrs.2017.03.026","article-title":"Emerging therapeutic uses of direct-acting oral anticoagulants: an evidence-based perspective","volume":"120","author":"Raschi","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.07.016_bib0770","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0775","unstructured":"FDA, ANDEXXA label information, (n.d.) https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM606687.pdf (Accessed 4 July 2018)."},{"key":"10.1016\/j.phrs.2018.07.016_bib0780","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-Glycoprotein transport system and cardiovascular drugs","volume":"61","author":"Wessler","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0785","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/clpt.2014.49","article-title":"Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity","volume":"95","author":"Oh","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0790","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FJC.0b013e3182970991","article-title":"The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor","volume":"62","author":"Mendell","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0795","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0800","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamainternmed.2014.946","article-title":"Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin","volume":"174","author":"Davidson","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0805","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00228-012-1304-8","article-title":"Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers","volume":"69","author":"H\u00e4rtter","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0810","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1160\/TH11-09-0634","article-title":"A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects","volume":"107","author":"Barrett","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.phrs.2018.07.016_bib0815","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00228-011-1205-2","article-title":"Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile","volume":"68","author":"Clemens","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0820","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/bcp.12393","article-title":"Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban","volume":"78","author":"Frost","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0825","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0830","article-title":"A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin","volume":"12","author":"Choi","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2018.07.016_bib0835","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.03.051","article-title":"Use of complementary therapies in patients with cardiovascular disease","volume":"98","author":"Yeh","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0840","article-title":"A review of potential harmful interactions between anticoagulant\/antiplatelet agents and Chinese herbal medicines","volume":"8","author":"Tsai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2018.07.016_bib0845","first-page":"841","article-title":"Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies","volume":"9","author":"Qiu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2018.07.016_bib0850","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FJC.0b013e31821cd888","article-title":"Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation","volume":"58","author":"Chan","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2014","key":"10.1016\/j.phrs.2018.07.016_bib0855","article-title":"Updates on the clinical evidenced herb-warfarin interactions","author":"Ge","year":"2014","journal-title":"Evid. Complement. Alternat. Med."},{"key":"10.1016\/j.phrs.2018.07.016_bib0860","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2125.2003.02051.x","article-title":"Effect of St John\u2019s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects","volume":"57","author":"Jiang","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0865","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2010.03672.x","article-title":"Warfarin and vitamin K intake in the era of pharmacogenetics","volume":"70","author":"Lurie","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0870","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","article-title":"Drug and dietary interactions of the new and emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.phrs.2018.07.016_bib0875","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00059-014-4188-9","article-title":"Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban","volume":"40","author":"St\u00f6llberger","year":"2015","journal-title":"Herz"},{"issue":"2017","key":"10.1016\/j.phrs.2018.07.016_bib0880","first-page":"e726","article-title":"AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the american college of Cardiology\/American heart association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.016_bib0885","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.amjcard.2017.09.030","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and end-stage renal disease","volume":"121","author":"Nishimura","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0890","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2018.07.016_bib0895","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0900","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2125.2001.01358.x","article-title":"The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers","volume":"51","author":"Yates","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0905","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0910","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2009.03384.x","article-title":"The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers","volume":"67","author":"Walker","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"22","key":"10.1016\/j.phrs.2018.07.016_bib0915","article-title":"Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism","volume":"12","author":"Harder","year":"2014","journal-title":"Thromb. J."},{"key":"10.1016\/j.phrs.2018.07.016_bib0920","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2018.07.016_bib0925","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.016_bib0930","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpdd.53","article-title":"Bioavailability and safety of the factor xa inhibitor edoxaban and the effects of quinidine in healthy subjects","volume":"2","author":"Matsushima","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818306273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818306273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T19:55:22Z","timestamp":1536609322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818306273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":186,"alternative-id":["S1043661818306273"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.07.016","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}